|
Ferring Overstates Efficacy for Cancer Drug: FDA
Ferring Pharmaceuticals has been handed an FDA untitled letter for overstating the efficacy and indication of its injectable prostate cancer drug Firmagon in a recent sales aid.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives